Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

被引:54
作者
McGettigan, JP
Foley, HD
Belyakov, IM
Berzofsky, JA
Pomerantz, RJ
Schnell, MJ
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Ctr Human Virol, Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA
[5] NCI, Metab Branch, Mol Immunogenet & Vaccine Res Sect, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.75.9.4430-4434.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Novel viral vectors that are able to induce both strong and long-lasting immune responses may be required as effective vaccines for human immunodeficiency virus type I (HIV-1) infection. Our previous experiments with a replication-competent vaccine strain-based rabies virus (RV) expressing HIV-1 envelope protein from a laboratory-adapted HIV-1 strain (NL4-3) and a primary HIV-1 isolate (89.6) shelved that RV-based vectors are excellent for B-cell priming. Here we report that cytotoxic T-Lymphocyte (CTL) responses against HIV-I gp160 are induced by recombinant RVs. Our results indicated that a single inoculation of mice with an RV expressing HIV-1 gp160 induced a solid and long-lasting memory CTL response specific for HIV-1 envelope protein. Moreover, CTLs from immunized mice were not restricted to the homologous HIV-I envelope protein and were able to cross-kill target cells expressing HIV-1 gp160 from heterologous HIV-1 strains. These studies further suggest promise for RV-based vectors to elicit a persistent immune response against HIV-1 and their potential utility as efficacious anti-HIV-1 vaccines.
引用
收藏
页码:4430 / 4434
页数:5
相关论文
共 38 条
[1]   PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES [J].
BABA, TW ;
JEONG, YS ;
PENNINCK, D ;
BRONSON, R ;
GREENE, MF ;
RUPRECHT, RM .
SCIENCE, 1995, 267 (5205) :1820-1825
[2]   Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques (vol 5, pg 194, 1999) [J].
Baba, TW ;
Liska, V ;
Khimani, AH ;
Ray, NB ;
Dailey, PJ ;
Penninck, D ;
Bronson, R ;
Greene, MF ;
McClure, HM ;
Martin, LN ;
Ruprecht, RM .
NATURE MEDICINE, 1999, 5 (05) :590-590
[3]   Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees [J].
Bagarazzi, ML ;
Boyer, JD ;
Javadian, MA ;
Chattergoon, MA ;
Shah, AR ;
Cohen, AD ;
Bennett, MK ;
Ciccarelli, RB ;
Ugen, KE ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :1351-1355
[4]  
Barnett SW, 1998, AIDS RES HUM RETROV, V14, pS299
[5]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[6]   The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12 [J].
Belyakov, IM ;
Ahlers, JD ;
Brandwein, BY ;
Earl, P ;
Kelsall, BL ;
Moss, B ;
Strober, W ;
Berzofsky, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) :2072-2081
[7]   Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus [J].
Berglund, P ;
QuesadaRolander, M ;
Putkonen, P ;
Biberfeld, G ;
Thorstensson, R ;
Liljestrom, P .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (17) :1487-1495
[8]   Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections [J].
Berzofsky, JA ;
Ahlers, JD ;
Derby, MA ;
Pendleton, CD ;
Arichi, T ;
Belyakov, IM .
IMMUNOLOGICAL REVIEWS, 1999, 170 :151-172
[9]   T lymphocyte responses in HIV-1 infection: implications for vaccine development [J].
Brander, C ;
Walker, B .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) :451-459
[10]   Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].
Cafaro, A ;
Caputo, A ;
Fracasso, C ;
Maggiorella, MT ;
Goletti, D ;
Baroncelli, S ;
Pace, M ;
Sernicola, L ;
Koanga-Mogtomo, ML ;
Betti, M ;
Borsetti, A ;
Belli, R ;
Åkerblom, L ;
Corrias, F ;
Buttò, S ;
Heeney, J ;
Verani, P ;
Titti, F ;
Ensoli, B .
NATURE MEDICINE, 1999, 5 (06) :643-650